Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

The study focused on why people with severe high blood pressure often develop thickened arteries and small blood vessels in ...

In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.

HKU5-CoV-2 can bind to the human angiotensin-converting enzyme (ACE2) receptor, the same receptor used by SARS-CoV-2 to infect human cells, as per the research. “We report the discovery and isolation ...